• Home
  1. Home
  2. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer
Scientific article
OA Policy
English

Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer

ContributorsAllal, Abdelkarim Said; Zwahlen, Daniel; Becker, Minerva; Dulguerov, Pavelorcid; Mach, Nicolas
Published inThe cancer journal, vol. 12, no. 1, p. 63-68
Publication date2006
Abstract

This study was conducted to determine the maximum tolerated dose of docetaxel when administered concomitantly with radical hyperfractionated radiotherapy and cisplatin in patients with locally advanced head and neck cancer.

Keywords
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects
  • Carcinoma, Squamous Cell/pathology/therapy
  • Cisplatin/administration & dosage/adverse effects
  • Combined Modality Therapy
  • Deglutition Disorders/etiology
  • Dose Fractionation
  • Dose-Response Relationship, Drug
  • Female
  • Head and Neck Neoplasms/pathology/therapy
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Mucositis/etiology
  • Neck Dissection
  • Neoplasm Staging
  • Taxoids/administration & dosage/adverse effects
  • Treatment Outcome
Affiliation entities
Research groups
Citation (ISO format)
ALLAL, Abdelkarim Said et al. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer. In: The cancer journal, 2006, vol. 12, n° 1, p. 63–68.
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN1528-9117
692views
525downloads

Technical informations

Creation10/28/2013 8:08:00 PM
First validation10/28/2013 8:08:00 PM
Update time10/08/2024 3:17:44 PM
Status update10/08/2024 3:17:44 PM
Last indexation10/30/2024 3:47:41 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack